Benjamin Bitler
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 45 | 2025 | 565 | 12.850 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 12 | 2025 | 115 | 4.600 |
Why?
| | Cystadenocarcinoma, Serous | 7 | 2024 | 77 | 3.160 |
Why?
| | Histone-Lysine N-Methyltransferase | 4 | 2024 | 136 | 2.270 |
Why?
| | Drug Resistance, Neoplasm | 11 | 2024 | 801 | 2.190 |
Why?
| | Claudin-4 | 4 | 2025 | 15 | 2.150 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3412 | 2.130 |
Why?
| | Genomic Instability | 2 | 2025 | 53 | 1.740 |
Why?
| | Fallopian Tubes | 3 | 2024 | 31 | 1.730 |
Why?
| | Nuclear Proteins | 10 | 2018 | 712 | 1.560 |
Why?
| | Tumor Microenvironment | 10 | 2024 | 674 | 1.520 |
Why?
| | Transcription Factors | 13 | 2023 | 1719 | 1.450 |
Why?
| | Gene Expression Regulation, Neoplastic | 21 | 2025 | 1396 | 1.420 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2024 | 872 | 1.390 |
Why?
| | Phthalazines | 3 | 2019 | 45 | 1.370 |
Why?
| | Piperazines | 3 | 2019 | 350 | 1.180 |
Why?
| | Polycomb Repressive Complex 1 | 3 | 2024 | 50 | 1.060 |
Why?
| | Cellular Senescence | 7 | 2019 | 189 | 1.060 |
Why?
| | Antineoplastic Agents | 7 | 2024 | 2129 | 1.020 |
Why?
| | Cell Proliferation | 12 | 2024 | 2475 | 1.010 |
Why?
| | BRCA2 Protein | 5 | 2024 | 63 | 0.930 |
Why?
| | Tryptophan Oxygenase | 2 | 2024 | 34 | 0.920 |
Why?
| | Autophagy | 2 | 2024 | 284 | 0.910 |
Why?
| | Female | 61 | 2025 | 73304 | 0.880 |
Why?
| | Poly(ADP-ribose) Polymerases | 3 | 2025 | 98 | 0.870 |
Why?
| | Neoplasms | 6 | 2023 | 2671 | 0.840 |
Why?
| | Histocompatibility Antigens | 2 | 2024 | 105 | 0.830 |
Why?
| | Mucin-1 | 4 | 2012 | 21 | 0.810 |
Why?
| | Mice | 29 | 2024 | 17787 | 0.810 |
Why?
| | Indoles | 4 | 2025 | 412 | 0.790 |
Why?
| | Ovary | 2 | 2022 | 221 | 0.780 |
Why?
| | Breast Neoplasms | 6 | 2024 | 2253 | 0.750 |
Why?
| | Protein-Arginine N-Methyltransferases | 2 | 2019 | 27 | 0.740 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 2 | 2021 | 27 | 0.730 |
Why?
| | DNA-Binding Proteins | 9 | 2020 | 1502 | 0.730 |
Why?
| | Neoplasms, Glandular and Epithelial | 4 | 2018 | 49 | 0.720 |
Why?
| | Humans | 75 | 2025 | 137585 | 0.710 |
Why?
| | Animals | 41 | 2025 | 36940 | 0.700 |
Why?
| | Mutation | 10 | 2022 | 3958 | 0.700 |
Why?
| | Ascites | 1 | 2021 | 46 | 0.690 |
Why?
| | Up-Regulation | 5 | 2020 | 843 | 0.680 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 249 | 0.680 |
Why?
| | ErbB Receptors | 5 | 2024 | 614 | 0.680 |
Why?
| | Genomics | 2 | 2024 | 795 | 0.660 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 63 | 0.660 |
Why?
| | Epoxy Compounds | 1 | 2020 | 33 | 0.660 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 46 | 0.650 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 15 | 0.640 |
Why?
| | Endometrial Neoplasms | 4 | 2025 | 201 | 0.640 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 389 | 0.620 |
Why?
| | Metabolomics | 1 | 2024 | 678 | 0.610 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 900 | 0.580 |
Why?
| | Signal Transduction | 10 | 2024 | 5079 | 0.580 |
Why?
| | Wnt Signaling Pathway | 4 | 2021 | 192 | 0.570 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 404 | 0.560 |
Why?
| | Proteomics | 1 | 2024 | 1111 | 0.560 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2015 | 67 | 0.550 |
Why?
| | Pyridones | 2 | 2018 | 168 | 0.540 |
Why?
| | Membrane Proteins | 4 | 2019 | 1164 | 0.540 |
Why?
| | Fatty Acids | 1 | 2020 | 443 | 0.520 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1276 | 0.510 |
Why?
| | Wnt Proteins | 2 | 2021 | 133 | 0.500 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 6 | 2020 | 51 | 0.490 |
Why?
| | Cell Nucleus | 3 | 2025 | 620 | 0.490 |
Why?
| | Histone Deacetylases | 1 | 2017 | 215 | 0.480 |
Why?
| | DNA Repair | 4 | 2025 | 231 | 0.470 |
Why?
| | B7-H1 Antigen | 3 | 2024 | 217 | 0.470 |
Why?
| | Methyltransferases | 1 | 2015 | 78 | 0.440 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 411 | 0.420 |
Why?
| | Anoikis | 3 | 2023 | 31 | 0.410 |
Why?
| | Peptides | 3 | 2023 | 985 | 0.400 |
Why?
| | Tryptophan | 2 | 2024 | 183 | 0.400 |
Why?
| | Biological Assay | 1 | 2013 | 124 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 437 | 0.390 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 94 | 0.390 |
Why?
| | Azepines | 3 | 2017 | 90 | 0.390 |
Why?
| | Cell Survival | 3 | 2025 | 1120 | 0.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1692 | 0.380 |
Why?
| | Triazoles | 3 | 2017 | 147 | 0.360 |
Why?
| | Gene Expression Profiling | 6 | 2023 | 1774 | 0.360 |
Why?
| | Carcinogenesis | 3 | 2024 | 217 | 0.360 |
Why?
| | Histones | 3 | 2023 | 636 | 0.350 |
Why?
| | Disease Progression | 8 | 2024 | 2757 | 0.350 |
Why?
| | Inflammation | 2 | 2023 | 2837 | 0.330 |
Why?
| | Cells | 1 | 2010 | 25 | 0.330 |
Why?
| | Alternative Splicing | 2 | 2024 | 229 | 0.330 |
Why?
| | Mice, Transgenic | 6 | 2024 | 2167 | 0.320 |
Why?
| | Apoptosis | 6 | 2024 | 2553 | 0.320 |
Why?
| | Neoplasm Invasiveness | 2 | 2024 | 510 | 0.320 |
Why?
| | Neoplasm Grading | 5 | 2024 | 307 | 0.320 |
Why?
| | Transcriptome | 3 | 2024 | 971 | 0.310 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2024 | 528 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2025 | 1079 | 0.300 |
Why?
| | BRCA1 Protein | 3 | 2021 | 76 | 0.290 |
Why?
| | Carcinoma | 1 | 2010 | 240 | 0.280 |
Why?
| | Fibroblasts | 1 | 2013 | 996 | 0.280 |
Why?
| | RNA, Small Interfering | 5 | 2020 | 622 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 648 | 0.280 |
Why?
| | Piperidines | 2 | 2019 | 206 | 0.280 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.270 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 365 | 0.260 |
Why?
| | beta Catenin | 3 | 2022 | 253 | 0.260 |
Why?
| | Peptide Fragments | 1 | 2010 | 706 | 0.250 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2018 | 210 | 0.250 |
Why?
| | Oncogenes | 2 | 2019 | 116 | 0.240 |
Why?
| | Imidazoles | 2 | 2024 | 238 | 0.240 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2025 | 50 | 0.230 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2025 | 43 | 0.230 |
Why?
| | Cell Cycle | 3 | 2025 | 601 | 0.230 |
Why?
| | Prognosis | 3 | 2024 | 4030 | 0.230 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2024 | 34 | 0.230 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2024 | 7 | 0.230 |
Why?
| | Amino Acid Transport System ASC | 1 | 2024 | 12 | 0.220 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 56 | 0.220 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 48 | 0.220 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 224 | 0.220 |
Why?
| | Ligands | 2 | 2024 | 664 | 0.220 |
Why?
| | DNA Transposable Elements | 1 | 2024 | 121 | 0.210 |
Why?
| | Wnt4 Protein | 2 | 2024 | 18 | 0.210 |
Why?
| | Lysine | 2 | 2023 | 294 | 0.210 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 37 | 0.210 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2016 | 100 | 0.210 |
Why?
| | Chromatin | 3 | 2025 | 519 | 0.210 |
Why?
| | Repressor Proteins | 2 | 2018 | 427 | 0.210 |
Why?
| | Exons | 1 | 2024 | 355 | 0.210 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 28 | 0.210 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.200 |
Why?
| | DNA Damage | 3 | 2022 | 420 | 0.200 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 20 | 0.200 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2022 | 3 | 0.200 |
Why?
| | Cell Movement | 3 | 2018 | 967 | 0.200 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 92 | 0.190 |
Why?
| | Indazoles | 2 | 2021 | 69 | 0.190 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 90 | 0.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 210 | 0.190 |
Why?
| | Cell Cycle Checkpoints | 4 | 2019 | 98 | 0.190 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 13 | 0.190 |
Why?
| | Down-Regulation | 4 | 2022 | 657 | 0.190 |
Why?
| | Tumor Cells, Cultured | 3 | 2019 | 955 | 0.190 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2021 | 18 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 313 | 0.180 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 50 | 0.180 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2024 | 202 | 0.180 |
Why?
| | Granulosa Cells | 1 | 2021 | 33 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 449 | 0.180 |
Why?
| | Antigen Presentation | 1 | 2022 | 218 | 0.180 |
Why?
| | RNA Interference | 3 | 2019 | 469 | 0.180 |
Why?
| | Epigenomics | 1 | 2021 | 115 | 0.180 |
Why?
| | Transfection | 3 | 2021 | 945 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1250 | 0.180 |
Why?
| | Ovarian Follicle | 1 | 2021 | 72 | 0.170 |
Why?
| | Proteins | 2 | 2017 | 1009 | 0.170 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 327 | 0.170 |
Why?
| | Lipids | 1 | 2025 | 672 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 86 | 0.170 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 363 | 0.170 |
Why?
| | Macrophages | 3 | 2024 | 1547 | 0.170 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 447 | 0.170 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 840 | 0.170 |
Why?
| | Immunity | 2 | 2022 | 143 | 0.170 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.160 |
Why?
| | Computational Biology | 1 | 2024 | 644 | 0.160 |
Why?
| | Wnt3A Protein | 1 | 2019 | 10 | 0.160 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 172 | 0.160 |
Why?
| | Immunotherapy | 2 | 2021 | 641 | 0.160 |
Why?
| | Neoplasm Transplantation | 2 | 2011 | 257 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2024 | 778 | 0.160 |
Why?
| | Acyltransferases | 1 | 2019 | 57 | 0.160 |
Why?
| | Immunity, Innate | 2 | 2024 | 828 | 0.160 |
Why?
| | Receptors, Adiponectin | 1 | 2019 | 19 | 0.160 |
Why?
| | Transcription, Genetic | 4 | 2024 | 1457 | 0.160 |
Why?
| | Gene Frequency | 1 | 2021 | 521 | 0.160 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 332 | 0.160 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 60 | 0.160 |
Why?
| | Sequence Analysis, DNA | 2 | 2021 | 812 | 0.150 |
Why?
| | Amino Acid Sequence | 4 | 2015 | 2139 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2023 | 752 | 0.150 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2019 | 59 | 0.150 |
Why?
| | NF-kappa B | 1 | 2023 | 691 | 0.150 |
Why?
| | CA-125 Antigen | 1 | 2018 | 14 | 0.150 |
Why?
| | Heterografts | 1 | 2019 | 138 | 0.150 |
Why?
| | Protein Processing, Post-Translational | 2 | 2021 | 465 | 0.150 |
Why?
| | Survival Rate | 2 | 2020 | 1972 | 0.150 |
Why?
| | Chloride Channels | 1 | 2018 | 35 | 0.150 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 53 | 0.150 |
Why?
| | Drug Repositioning | 1 | 2018 | 35 | 0.140 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2018 | 126 | 0.140 |
Why?
| | Genetic Testing | 1 | 2021 | 460 | 0.140 |
Why?
| | Histone Deacetylase 6 | 1 | 2017 | 17 | 0.140 |
Why?
| | Mice, SCID | 3 | 2018 | 367 | 0.140 |
Why?
| | Paclitaxel | 1 | 2019 | 230 | 0.140 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 617 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 191 | 0.140 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1236 | 0.140 |
Why?
| | Claudins | 1 | 2017 | 25 | 0.130 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2020 | 257 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.130 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 95 | 0.130 |
Why?
| | HMGB2 Protein | 1 | 2016 | 5 | 0.130 |
Why?
| | Secretory Pathway | 1 | 2016 | 8 | 0.130 |
Why?
| | Mevalonic Acid | 1 | 2016 | 13 | 0.130 |
Why?
| | Heterochromatin | 2 | 2016 | 53 | 0.130 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2016 | 14 | 0.130 |
Why?
| | Tight Junctions | 1 | 2017 | 76 | 0.130 |
Why?
| | Acetylation | 1 | 2017 | 248 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 806 | 0.130 |
Why?
| | Genetics, Population | 2 | 2008 | 214 | 0.130 |
Why?
| | Mammary Glands, Animal | 1 | 2017 | 129 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 283 | 0.130 |
Why?
| | RNA, Long Noncoding | 1 | 2018 | 181 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1060 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2019 | 455 | 0.120 |
Why?
| | Tumor Burden | 1 | 2017 | 309 | 0.120 |
Why?
| | Mice, Nude | 2 | 2015 | 698 | 0.120 |
Why?
| | Endopeptidases | 1 | 2015 | 90 | 0.120 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 366 | 0.120 |
Why?
| | Genetic Loci | 1 | 2016 | 288 | 0.120 |
Why?
| | Biomarkers | 2 | 2024 | 4149 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4295 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1317 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.110 |
Why?
| | Epithelial Cells | 2 | 2017 | 1096 | 0.110 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2013 | 16 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1081 | 0.100 |
Why?
| | Pyrimidine Nucleotides | 1 | 2013 | 3 | 0.100 |
Why?
| | Purine Nucleotides | 1 | 2013 | 12 | 0.100 |
Why?
| | beta-Galactosidase | 1 | 2013 | 78 | 0.100 |
Why?
| | CCAAT-Binding Factor | 1 | 2013 | 4 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2691 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7635 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2057 | 0.100 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.100 |
Why?
| | Aged | 5 | 2025 | 23961 | 0.100 |
Why?
| | Genes, Reporter | 1 | 2013 | 269 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 75 | 0.090 |
Why?
| | Middle Aged | 6 | 2025 | 33479 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 860 | 0.090 |
Why?
| | Proteome | 1 | 2016 | 472 | 0.090 |
Why?
| | RNA Helicases | 1 | 2011 | 30 | 0.090 |
Why?
| | Genes, ras | 1 | 2011 | 97 | 0.090 |
Why?
| | Wnt-5a Protein | 1 | 2011 | 23 | 0.090 |
Why?
| | Golgi Apparatus | 1 | 2011 | 100 | 0.090 |
Why?
| | Interferons | 2 | 2024 | 202 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5131 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2900 | 0.090 |
Why?
| | Gene Flow | 2 | 2008 | 86 | 0.090 |
Why?
| | Cell Line | 4 | 2021 | 2847 | 0.080 |
Why?
| | Models, Biological | 3 | 2019 | 1783 | 0.080 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2024 | 197 | 0.080 |
Why?
| | Endosomes | 1 | 2011 | 136 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2010 | 68 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2607 | 0.080 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2010 | 124 | 0.080 |
Why?
| | Arachnida | 1 | 2008 | 5 | 0.080 |
Why?
| | Cloning, Molecular | 1 | 2010 | 534 | 0.080 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2011 | 199 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2526 | 0.080 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2009 | 68 | 0.070 |
Why?
| | Protein Binding | 2 | 2016 | 2224 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2024 | 730 | 0.070 |
Why?
| | Cytoplasm | 1 | 2009 | 274 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1043 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2022 | 1738 | 0.070 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 658 | 0.070 |
Why?
| | Trans-Activators | 1 | 2010 | 398 | 0.070 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2007 | 33 | 0.070 |
Why?
| | Transforming Growth Factor alpha | 1 | 2007 | 57 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1389 | 0.070 |
Why?
| | Cactaceae | 1 | 2006 | 5 | 0.070 |
Why?
| | Triatoma | 1 | 2006 | 7 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2018 | 601 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 861 | 0.060 |
Why?
| | Phylogeny | 2 | 2008 | 904 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 35 | 0.060 |
Why?
| | Drosophila | 1 | 2006 | 154 | 0.060 |
Why?
| | DNA End-Joining Repair | 1 | 2025 | 20 | 0.060 |
Why?
| | Genetic Variation | 2 | 2008 | 991 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 660 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2008 | 493 | 0.060 |
Why?
| | Retinal Dehydrogenase | 2 | 2016 | 29 | 0.060 |
Why?
| | Protein Transport | 2 | 2019 | 445 | 0.060 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 67 | 0.050 |
Why?
| | Cytokine TWEAK | 1 | 2023 | 1 | 0.050 |
Why?
| | Transcription Factor RelB | 1 | 2023 | 4 | 0.050 |
Why?
| | TWEAK Receptor | 1 | 2023 | 5 | 0.050 |
Why?
| | Tumor Necrosis Factors | 1 | 2023 | 11 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 404 | 0.050 |
Why?
| | Muscular Atrophy | 1 | 2023 | 86 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 129 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 190 | 0.050 |
Why?
| | Cachexia | 1 | 2023 | 71 | 0.050 |
Why?
| | Homologous Recombination | 1 | 2022 | 28 | 0.050 |
Why?
| | Recombinational DNA Repair | 1 | 2022 | 16 | 0.050 |
Why?
| | Carboplatin | 1 | 2023 | 144 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2023 | 164 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 767 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 305 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 29 | 0.050 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 32 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 123 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 499 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1993 | 0.040 |
Why?
| | Tumor Escape | 1 | 2020 | 42 | 0.040 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 5757 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 110 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 794 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2019 | 65 | 0.040 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2020 | 104 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Computer Simulation | 1 | 2023 | 978 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 239 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1226 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 318 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 433 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 125 | 0.040 |
Why?
| | DNA | 1 | 2025 | 1459 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 594 | 0.040 |
Why?
| | Gene Amplification | 1 | 2018 | 104 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2022 | 1178 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1325 | 0.040 |
Why?
| | Mitosis | 1 | 2019 | 192 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2018 | 102 | 0.040 |
Why?
| | Desert Climate | 2 | 2008 | 16 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1060 | 0.040 |
Why?
| | Arizona | 2 | 2008 | 81 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 220 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3556 | 0.030 |
Why?
| | Pyridines | 1 | 2021 | 506 | 0.030 |
Why?
| | DNA Helicases | 1 | 2018 | 145 | 0.030 |
Why?
| | Mexico | 2 | 2008 | 225 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 628 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 382 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1759 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 209 | 0.030 |
Why?
| | DNA, Mitochondrial | 2 | 2008 | 200 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1242 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2016 | 118 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2016 | 173 | 0.030 |
Why?
| | Sumoylation | 1 | 2015 | 16 | 0.030 |
Why?
| | Lactation | 1 | 2017 | 181 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1704 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2016 | 180 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 177 | 0.030 |
Why?
| | Models, Genetic | 2 | 2008 | 600 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 513 | 0.030 |
Why?
| | Gene Silencing | 1 | 2015 | 195 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2016 | 433 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 434 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1272 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1724 | 0.030 |
Why?
| | E2F7 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2013 | 6 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 532 | 0.030 |
Why?
| | Nucleosides | 1 | 2013 | 27 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2013 | 52 | 0.030 |
Why?
| | Melanoma | 1 | 2020 | 760 | 0.030 |
Why?
| | Adult | 2 | 2025 | 37929 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2012 | 177 | 0.020 |
Why?
| | ras Proteins | 1 | 2013 | 153 | 0.020 |
Why?
| | Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 6 | 0.020 |
Why?
| | Genes, BRCA1 | 1 | 2011 | 40 | 0.020 |
Why?
| | Time Factors | 2 | 2016 | 6828 | 0.020 |
Why?
| | Sorting Nexins | 1 | 2011 | 12 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2011 | 59 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2011 | 138 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3015 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2011 | 155 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 224 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 346 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 172 | 0.020 |
Why?
| | Protein Folding | 1 | 2011 | 280 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 636 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 327 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2011 | 665 | 0.020 |
Why?
| | Geography | 1 | 2008 | 200 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3196 | 0.020 |
Why?
| | Population Dynamics | 1 | 2008 | 151 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 306 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4193 | 0.020 |
Why?
| | Haplotypes | 1 | 2008 | 494 | 0.020 |
Why?
| | Genes, Insect | 1 | 2006 | 22 | 0.020 |
Why?
| | Cytochromes b | 1 | 2006 | 10 | 0.020 |
Why?
| | Electron Transport Complex IV | 1 | 2006 | 60 | 0.020 |
Why?
| | Insect Vectors | 1 | 2006 | 39 | 0.020 |
Why?
| | Chagas Disease | 1 | 2006 | 44 | 0.020 |
Why?
| | Lymphoma | 1 | 2007 | 208 | 0.020 |
Why?
| | Host-Parasite Interactions | 1 | 2006 | 114 | 0.010 |
Why?
| | Bayes Theorem | 1 | 2006 | 405 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 6763 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2833 | 0.010 |
Why?
| | Firefly Luciferin | 1 | 1957 | 1 | 0.010 |
Why?
| | Diptera | 1 | 1957 | 30 | 0.010 |
Why?
| | Luciferases | 1 | 1957 | 150 | 0.010 |
Why?
| | Male | 1 | 2015 | 67762 | 0.000 |
Why?
|
|
Bitler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|